how InvestingPro’s Fair Value spotted Organon’s 69% gain potential
On February 3, 2026, InvestingPro's Fair Value analysis identified Organon & Co. (NYSE: OGN) as a potentially undervalued stock, projecting a significant upside of 69%. At that time, the stock was trading at just $8.00 per share, having declined over 40% from its historical highs. The analysis, which combines multiple valuation methods, revealed a 53.37% discount to Organon's intrinsic value, with a fair value estimate of $12.27 per share.
By June 28, 2026, the stock had surged 68.75% to reach its target price of $13.50, validating the Fair Value prediction. Factors contributing to this gain included Sun Pharma's $12 billion acquisition bid, Organon's clearance of misconduct allegations, and the approval of its tocilizumab biosimilar for expanded use. Despite a slight revenue decline to $6.1 billion, earnings per share improved to $0.80, showcasing operational efficiency.
InvestingPro's Fair Value methodology aggregates various valuation approaches to estimate intrinsic value, helping investors spot market mispricing opportunities.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
